Department of Diabetes and Endocrinology, Peninsula Health, 2 Hastings Road, Frankston, VIC, 3199, Australia.
Osteoporos Int. 2022 Jul;33(7):1625-1629. doi: 10.1007/s00198-022-06369-z. Epub 2022 Mar 14.
Denosumab delays and prevents skeletal related events in patients with malignancy-related bony metastases. Rarely, denosumab discontinuation can lead to rebound hypercalcemia in the setting of increased bone resorption. We describe the case of a 49-year-old breast cancer survivor who developed rebound hypercalcemia after cessation of long-term denosumab. She had been treated with 42 doses of denosumab between August 2013 and March 2020 and 8 months after her last dose of denosumab developed symptomatic hypercalcemia. Parathyroid hormone levels were suppressed, and active malignancy was excluded based on biochemical and radiological testing. She required treatment with intravenous bisphosphonates on three separate occasions in order to achieve long-term normalization of her hypercalcemia. Rebound hypercalcemia post-denosumab cessation is a rare but serious complication that clinicians should be aware of.
地舒单抗可延迟和预防恶性肿瘤骨转移患者的骨骼相关事件。极少数情况下，地舒单抗停药后可导致骨吸收增加而发生反跳性高钙血症。我们描述了一例 49 岁乳腺癌幸存者在停止长期地舒单抗治疗后发生反跳性高钙血症的病例。她在 2013 年 8 月至 2020 年 3 月期间接受了 42 剂地舒单抗治疗，最后一次用药后 8 个月时出现症状性高钙血症。甲状旁腺激素水平受到抑制，且基于生化和影像学检查排除了活动性恶性肿瘤。她需要静脉注射双膦酸盐治疗 3 次，才能使高钙血症长期恢复正常。地舒单抗停药后发生反跳性高钙血症是一种罕见但严重的并发症，临床医生应有所了解。
